Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development

Published on: 
BioPharm International, BioPharm International-10-01-2001, Volume 14, Issue 10

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Manufacturing processes for murine monoclonal antibodies (mMABs) used in therapeutic applications must address more safety concerns than those used for in vitro diagnostics. Adequate characterization helps ensure that the mMAb retains its functional integrity after more extensive processing.